BioSpace News Archive

Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced promising preclinical safety results with berdazimer sodium in a 14-day GLP repeat dose intranasal toxicity study.

Ichnos Sciences Inc. announced that Sonia Quaratino , M.D., Ph.D., has been appointed as an independent member of its Board of Directors.

Schrödinger to Present at Jefferies London Healthcare Conference

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to discuss financial results for third quarter ended September 30, 2021.

Lantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that management will be participating in two upcoming investor conferences.

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced that it has completed an amendment to Pulmatrix’s agreement with Cipla Technologies, LLC for the development and commercialization of Pulmazole.

Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis.

Enzo Biochem, Inc. announced today that on November 8, 2021, it granted equity awards to Hamid Erfanian.